At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 112 enrolled
Drug / intervention
Obicetrapib 5mg +2 moredrug
Likely dose
Obicetrapib 5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild Dyslipidemia
In Brief
A Phase 2 clinical trial evaluating Obicetrapib 5mg, Ezetimibe 10mg, and 1 other intervention for Dyslipidemias and 2 related conditions. Completed, enrolled 112 participants across 9 sites in 2 countries.
Detailed Summary
This study will be a placebo-controlled, double-blind, randomized, phase 2 study in participants with mild dyslipidemia to evaluate the efficacy, safety, and tolerability of obicetrapib and ezetimibe combination therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDyslipidemias, High Cholesterol, Hypercholesterolemia
CountriesNetherlands, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartFeb 2021
First PostedFeb 2021
Primary CompletionMay 2021
Study CompletionJun 2021
TodayJul 2026
First PostedFeb 25, 2021
Enrollment StartFeb 23, 2021
Primary CompletionMay 7, 2021
Study CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 5.4 years ago
Interventions
Obicetrapib 5mgdrug
tablet
Ezetimibe 10mgdrug
tablet
Placeboother
tablet